N Jr Biography and Net Worth

Director of GeoVax Labs

Mr. Spencer joined the Board of Directors in September 2006. Mr. Spencer is a registered Certified Public Accountant in four states, and he was a Partner at Ernst & Young LLP (“EY”) where he spent more than 38 years until he retired in 2000. While at EY, Mr. Spencer was the partner in charge of the Firm’s life sciences practice for the Southeastern United States, and his clients included numerous publicly owned and privately held medical technology companies.

Since his retirement from EY, Mr. Spencer has served as the Audit Committee Chair on the Boards of ten other life sciences companies. He also served as the temporary Chief Financial Officer of a life sciences company while that company prepared for its initial public offering. In addition, he has served as a consultant to various companies with respect to financial accounting matters.

Mr. Spencer earned a Bachelor of Science degree at Syracuse University and an MBA degree at Babson College. He also attended the Harvard Business School Advanced Management Program.

What is N Spencer Jr's net worth?: The estimated net worth of N Spencer Jr is at least $131.33 as of April 10th, 2025. Jr owns 456 shares of GeoVax Labs stock worth more than $131 as of October 12th. This net worth evaluation does not reflect any other investments that Jr may own. Learn More about N Spencer Jr's net worth.
How do I contact N Spencer Jr?: The corporate mailing address for Jr and other GeoVax Labs executives is 1955 Lake Park Drive, Suite 300, Smyrna, GA. GeoVax Labs can also be reached via phone at (678) 384-7220 and via email at [email protected]. Learn More on N Spencer Jr's contact information.
Has N Spencer Jr been buying or selling shares of GeoVax Labs?: N Spencer Jr has not been actively trading shares of GeoVax Labs within the last three months. Most recently, on Thursday, April 10th, N Spencer Jr bought 400 shares of GeoVax Labs stock. The stock was acquired at an average cost of $24.50 per share, with a total value of $9,800.00. Following the completion of the transaction, the director now directly owns 456 shares of the company's stock, valued at $11,172. Learn More on N Spencer Jr's trading history.
Who are GeoVax Labs' active insiders?: GeoVax Labs' insider roster includes David Dodd (CEO), N Jr (Director), Mark Reynolds (CFO), and John Sharkey (VP). Learn More on GeoVax Labs' active insiders.

N Spencer Jr Insider Trading History at GeoVax Labs

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/10/2025	Buy	400	$24.50	$9,800.00	456

N Spencer Jr Buying and Selling Activity at GeoVax Labs

GeoVax Labs Company Overview

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Today's Range

Now: $0.29

$0.28

$0.30

50 Day Range

MA: $0.52

$0.28

$0.77

2 Week Range

Now: $0.29

$0.27

$15.75

Volume

200,148 shs

Average Volume

1,935,183 shs

Market Capitalization

$2.12 million

P/E Ratio

N/A

Dividend Yield